Global Stem Cell Therapy Contract Manufacturing Market Research 2019-2030: Source of Stem Cells, Types of Stem Cells, Size of Contract Service Provider Company, Scale of Operation, Key Regions

News provided by

Dec 03, 2019, 12:00 ET

DUBLIN, Dec. 3, 2019 /PRNewswire/ -- The "Stem Cell Therapy Contract Manufacturing Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

The Stem Cell Therapies Contract Manufacturing Market, 2019 - 2030 report features an extensive study on contract service providers engaged in the development and manufacturing of stem cell therapies. The study features in-depth analyses, highlighting the capabilities of various stem cell therapy CMOs.

Advances in the fields of cell biology and regenerative medicine have led to the development of a variety of stem cell-based therapies for many cardiovascular, oncological, metabolic and musculoskeletal disorders. Driven by the revenues generated from stem cell therapies, the regenerative medicine market is anticipated to generate revenues worth USD 100 billion by 2030. With a promising pipeline of over 200 stem cell therapy candidates, it has become essential for developers to scale up the production of such therapeutic interventions. Given that stem cell therapy manufacturing requires highly regulated, state-of-the-art technologies, it is difficult for stakeholders to establish in-house expertise for large-scale manufacturing of stem cell therapies.

As a result, stem cell therapy developers have begun outsourcing their manufacturing operations to contract manufacturing organizations (CMOs). Specifically, small and mid-sized players in this sector tend to outsource a substantial proportion of clinical and commercial-scale manufacturing processes to contract service providers. In addition, even big pharma players, with established in-house capabilities, are gradually entering into long-term business relationships with CMOs in order to optimize resource utilization and manage costs.

According to a recent Nice Insight CDMO survey, about 55% of 700 respondents claimed to have collaborated with a contract service provider for clinical and commercial-scale product development requirements. Considering the prevalent trends, we believe that the stem cell therapy manufacturing market is poised to grow at a steady pace, driven by a robust pipeline of therapy candidates and technological advances aimed at mitigating challenges posed by conventional methods of production. Amidst tough competition, the availability of cutting-edge tools and technologies has emerged as a differentiating factor and is likely to grant a competitive advantage to certain CMOs over other players in the industry.

One of the key objectives of the report was to estimate the future size of the market. Based on parameters, such as increase in number of clinical studies, target patient population, anticipated adoption of stem cell therapies and expected variation in manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the mid to long term, for the period 2019-2030.

Amongst other elements, the report includes:

A detailed review of the contract manufacturing landscape for stem cell therapies, featuring a comprehensive list of active CMOs and analysis based on a number of parameters, such as year of establishment, company size, geographical location, number of stem cell therapy manufacturing facilities, source of stem cells (allogenic and autologous), types of services offered (culture development, stem cell identification / validation, stem cell banking, cryopreservation, logistics, fill / finish and regulatory filings), scale of operation (preclinical, clinical and commercial), types of stem cells (adult, embryonic and induced pluripotent) and therapeutic area (oncology and non-oncology).
An elaborate discussion of the various guidelines laid down by regulatory bodies related to stem cells and other cell-based therapies across various geographies, such as the North America (primarily the US), Europe and other regions.
Elaborate profiles of the key players based in North America, Europe and Asia-Pacific that have a diverse range of capabilities for the development, manufacturing and packaging of stem cell therapies. Each profile includes an overview of the company, its financial performance (if available), information on service portfolio, stem cell therapy manufacturing facilities, and details on partnerships, recent developments and an informed future outlook.
An analysis of the recent collaborations (signed since 2015) focused on the contract manufacturing of stem cell therapies, based on various parameters, such as year of agreement, type of agreement, scale of operation, source of stem cells used, types of stem cells and location of companies entering the partnership.
An informed estimate of the annual demand for stem cell therapies in terms of area (in square feet) dedicated to stem-cell related operations, based on various parameters, such as target patient population, price of the therapy, dosing frequency and dose strength.
A detailed capacity analysis, taking into consideration the manufacturing capacities of various stakeholders (small-sized, mid-sized and large CMOs) in the market, based on data gathered via secondary and primary research. It also provides the distribution of global stem cell therapy manufacturing capacity by company size (small-sized, mid-sized and large), and geography (North America, Europe and Asia-Pacific) and scale of operation (preclinical / clinical and commercial).
A detailed analysis to understand the relationship between the demand and supply in this field, comparing the presence of stem cell therapy developers and the availability / capability of contract manufacturers across different geographies.
An analysis to identify the key performance indicators for service providers active in the domain, based on the information gathered via secondary research and primary research.

In order to provide a detailed future outlook, our projections have been segmented on the basis of:

[A] source of stem cells (autologous and allogenic)
[B] types of stem cells (adult, embryonic and induced pluripotent)
[C] size of contract service provider company (small-sized, mid-sized and large)
[D] scale of operation (preclinical, clinical and commercial)
[E] key geographical regions (North America, Europe and Asia and rest of the world)

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. Regulatory Landscape

6. Stem Cell Therapy Contract Manufacturers In North America

7. Stem Cell Therapy Contract Manufacturers In Europe And Asia-Pacific

8. Partnerships And Collaboration

9. Contract Manufacturing Opportunity Assessment

10. Capacity Analysis

11. Demand Analysis

12. Market Forecast

13. Key Performance Indicators

14. Concluding Remark

15. Executive Insights

16. Appendix 1: Tabulated Data

17. Appendix 2: List Of Companies And Organizations

3P Biopharmaceuticals
AbbVie
Accellta
Adaptimmune
Advancecells
Advanced Cell Technology
Aegle Therapeutics
Aelan Cell Technologies
AGC
Ajinomoto
Ajinomoto Kohjin Bio
AllCells
Allele Biotechnology & Pharmaceuticals
Alpine BioTherapeutics
American CryoStem
Anagenesis Biotechnologies
Andalusian Initiative for Advanced Therapies
Angel Biotechnology
Anterogen
apceth Biopharma
Aspire Health Science
Astellas Pharma
Asterias Biotherapeutics
AstraZeneca
Athersys
Atlantic Bio GMP
Avid Bioservices
Axcelead Drug Discovery Partners
Axiogenesis
Baxter International
Bellicum Pharmaceuticals
Ben-Gurion University of the Negev
Bio Elpida
BioCardia
Bioinova
BioIVT
BioLife Cell Bank
Biological and Cellular GMP Manufacturing Facility, City of Hope
BioNTech IMFS
BioRestorative Therapies
bluebird bio
BlueRock Therapeutics
Bone Therapeutics
BrainStorm Cell Therapeutics
Caladrius Biosciences
Capicor Therapeutics
CardioCell
CardioCreate
Case Western Reserve University School of Medicine
Cell and Gene Therapy Catapult
Cell Cure Neurosciences
Cell Source
Cell Tech Pharmed
Cell Therapies
Cell Therapy and Regenerative Medicine, University of Utah
Cell Therapy Manufacturing Cooperative Research Centre
Cellect Biotechnology
Cellerant Therapeutics
CELLforCURE
CELLINK
CellProthera
Cells for Sight, Stem Cell Therapy Research Unit, University College London
Cellular Biomedicine Group
Cellular Therapy Core, University of Texas
Celther Polska
Center for Biomedical Engineering and Advanced Manufacturing, McMaster University
Center for Cell and Gene Therapy, Baylor College of Medicine
Center for Molecular Medicine Cologne
Center for Specialised Care & Research
Centre for Cell and Vector Production (CCVP)
Centre of Excellence for Cellular Therapy
Chiesi Farmaceutici
Clean Cells
ClinImmune Labs
CMC Biologics
Cognate BioServices
Colorado Center for Reproductive Medicine (CCRM)
Cook MyoSite
Corestem
Creative Medical Technology Holdings
Cryosite
Cryoviva Biotech
CSL Behring
Cynata Therapeutics
Cytopeutics
Cytori Therapeutics
Daiichi Sankyo
Dendreon
Digilab
DiscGenics
Duke University School of Medicine
Eli Lilly
Emory Personalized Immunotherapy Core
ExCellThera
Exopharm
Fate Therapeutics
Fibrocell
Florey Institute of Neuroscience and Mental Health
Fraunhofer Institute for Cell Therapy and Immunology
FUJIFILM Cellular Dynamics
FUJIFILM Irvine Scientific
Gamida Cell
Gates Biomanufacturing Facility
GE Healthcare
GenCure
Gene and Cell Therapy Lab, Institute of Translational Health Sciences
Genxbio
Genzyme Biosurgery
Global Cell Med
Global Stem Cells and Regenerative Medicine Acceleration Center
Grace Century
Guy's and St Thomas' Facility
Gwo XI Stem Cell Applied Technology
Harvard Stem Cell Institute, Harvard University
Healios
Helocyte
HemoGenyx Pharmaceuticals
Hemostemix
Histocell
Histogen
Holostem Terapie Avanzate
Ichor Therapeutics
ID Pharma
Institute of Liver & Biliary Sciences
Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami
International Stem Cell Corporation
iPS Academia Japan
IQVIA Stem Cell Center
Japan Tissue Engineering
Japanese Society for Regenerative Medicine
John Goldman Centre for Cellular Therapy
Johnson & Johnson
Kadimastem
Kangstem Biotech
KBI Biopharma
Kohjin-Bio
Kolon Life Sciences
Kyoto University
Kyushu University
Laboratory for Cell and Gene Medicine, University of Stanford
Life Stem Genetics
Lifecells
LifeSouth Community Blood Centers
Living Cell Technologies
Longeveron
Lonza
Magenta Therapeutics
MaSTherCell
Medeor Therapeutics
MEDINET
Medipost
Merck
Mesoblast
Michael J Fox Foundation for Parkinson's Research
Molecular and Cellular Therapeutics, University of Minnesota
Moraga Biotechnology
Morphogenesis
Nanion Technologies
National Eye Institute
Nature Cell
Neovii
Nestl Institute of Health Sciences
Neuralstem
NeuroGen Brain & Spine Institute
NeuroGeneration
New York Blood Center
NHS Blood and Transplant (NHSBT)
NIHR GOSH Biomedical Research Centre
Nikon CeLL innovation
Nohla Therapeutics
Novadip Biosciences
Novartis
Ocata Therapeutics
Octane Biotech
OhioHealth
OiDE BetaRevive
Orchard Therapeutics
Organogenesis
Orgenesis
Orisis Therapeutics
Personalized Stem Cells
Pfizer
PharmaCell
Pharmicell
Philip S Orsino Facility for Cell Therapy, Princess Margaret Hospital
Pluristem Therapeutics
Progenitor Cell Therapy (PCT)
Promethera Biosciences
Protide Pharmaceuticals
Provia Laboratories
Rayne Cell Therapy Suite, King's College London
Regeneris Medical
Regeneus
ReNeuron
Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation
RHEACELL
Roche
ROHTO Pharmaceutical
RoosterBio
RoslinCT
Roswell Park Cancer Institute
Royal Free Hospital
Samsung BioLogics
SanBio
Saneron CCEL Therapeutics
Sangamo Therapeutics
S-Biomedic
Sclnow Biotechnology
SCM Lifescience
Scottish National Blood Transfusion Service (SNBTS)
Sentien Biotechnologies
SeouLin Bioscience
Shanghai Biotechnology
Sistemic
SSM Health Cardinal Glennon Children's Hospital
Stem Cell Theranostics
Stem Cells Arabia
StemBioSys
STEMCELL Technologies
Stemedica Cell Technologies
StemGenn Therapeutics
Steminent Biotherapeutics
Stemline Therapeutics
Stemmatters
StemoniX
Stempeutics Research
Taiga Biotechnologies
Taiwan Bio Therapeutics
Takara Bio
Takeda Pharmaceutical
Terumo
Theracell
Tianhe Stem Cell Biotechnologies
Tianjin Ever Union Biotechnology
TiGenix
Tissue Genesis
TreeFrog Therapeutics
U.S. Stem Cell
UC Davis GMP Laboratory
UC Irvine Medical Center
UCI Beall Applied Innovation
Universal Cells
University Hospitals Case Medical Center
University of California
University of Manchester
University of Newcastle
Upstate Stem Cell cGMP Facility, University of Rochester
Vecura, Karolinska University Hospital
Vericel
ViaCyte
Viscofan
Viscofan BioEngineering
Vor Biopharma
Waisman Biomanufacturing
Worldwide Clinical Trials
WuXi Advanced Therapies
Xcelthera
Xellbiogene
YposKesi

For more information about this report visit https://www.researchandmarkets.com/r/jwfp7v

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets